Navigation Links
Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results
Date:5/7/2008

Company resumes commercial operations with first product sales since 2005

SEATTLE, May 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reported financial results for the quarter ended March 31, 2008. Total revenues for the quarter were $3.4 million compared to $20,000 for the first quarter of 2007. Gross product sales of Zevalin(R) (Ibritumomab Tiuxetan) reached $3.8 million in the first quarter of 2008.

Total operating expenses increased to $28.4 million for the quarter ended March 31, 2008 compared to $23.6 million for the same period in 2007 mainly as a result of increased expenses related to the creation of commercial infrastructure to support Zevalin and fees associated with capital structure advisory services. Net loss attributable to common shareholders for the quarter ended March 31, 2008, which includes a one-time inducement payment of $16.2 million to convert preferred shares into common shares, totaled $54.6 million ($0.77 per share) compared to $28.7 million ($0.76 per share) for the comparable period in 2007. The increase in net loss attributable to common shareholders was also due, in part, to an increase in interest expense and make-whole interest payments related to the 9% convertible senior notes and the loss recorded on the exchange of the 5.75% convertible senior subordinated and subordinated notes in 2008. This was offset by a gain on the derivative liability related to conversions of the 9% convertible senior notes. We also had a foreign exchange loss for the quarter ended March 31, 2008 compared to a gain for the same period in 2007.

The Company had approximately $15.3 million in cash and cash equivalents, securities available-for-sale, and interest receivable as of March 31, 2008. This does not include $6.2 million in restricted cash held in escrow and net proceeds, before fees and expenses, of approximately $22.9 million from the issuance on April 30, 2008 of preferred stock, convertib
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
2. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
3. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
4. Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008
5. Profarmas Gross Revenues Reached R$ 702.6 Million in the 1st Quarter 2008, a 26.5% Growth Over the Same Period Last Year
6. Precyse Solutions Launches Clinical Documentation Improvement Program to Assist Hospitals in Accelerating Revenues
7. Amilpar Revenues Increase by 32% and EBITDA Doubles in 2007
8. MEDRAD(R) Revenues Grow 10 Percent in 2007
9. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
10. Kendle Delivers Strong Growth in Revenues, New Business Authorizations and Operating Margin for Full-Year 2007; Announces Guidance for 2008
11. Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...onal Pediatric AIDS Initiative Will Improve... WASHINGTON, Aug. 29 /PRNewswire-FirstCall/ -- Th... government, Baylor College of Medicine, the,gover...S. President,s,Emergency Plan for AIDS Relief (PEP... improve care and treatment for children with HIV/...
(Date:8/29/2008).../ -- Conseco Insurance Company, a life,and health ...y of its new,indexed universal life insurance pro...de potential with downside protection., ConsecoLi... offers the,opportunity for long-term cash buildup...ents can customize their coverage levels with eigh...
(Date:8/29/2008)...SNewswire/ -- The U.S. Department of,Labor propose...public to,see exactly what goes into agency risk a...r http://edocket.access.gpo.gov/2008/E8-20179.htm...st available evidence and,scientific data are used...ards regulating occupational exposure to toxins in...
(Date:8/29/2008)...SNewswire/ -- The following is a,statement by Matt... Kids:, For the second time in a month, Philip Mo... and promotion of a concert in a developing countr...ngaging in cigarette,marketing that appeals to chi...s been forced to withdraw from,an August 30 reunio...
Breaking Medicine News(10 mins):Health News:Abbott Fund to Build First Pediatric HIV/AIDS Clinic in Tanzania 2Health News:Abbott Fund to Build First Pediatric HIV/AIDS Clinic in Tanzania 3Health News:Abbott Fund to Build First Pediatric HIV/AIDS Clinic in Tanzania 4Health News:ConsecoLifeOptions Launched by Conseco Insurance Company as New Universal Life Product 2Health News:Notice of Proposed Rulemaking on U.S. Department of Labor's Risk Assessment Procedures Published in Federal Register 2Health News:Philip Morris International Forced to Drop Another Concert Sponsorship; Philippines Health Department Applauded for Taking Action 2
...that the magnets that are sold in the market does ...t health problems//. Magnet that are advertised ov...ot posses any theoretical and experimental value. ...ful athletes mainly to relive pain but the researc...
...lized medicine, one should reevaluate new medicine...ry//, Ph.D., Dr. Berry, professor and chair of t...tics at The University of Texas M. D. Anderson Can...linical trials are designed and conducted in the U...
... Woodruff (R) said he had filed a bill (HB 1096) t...s delivering the baby// would endanger the life or... law to make performing an abortion a Class C felo...ar prison sentence. Woodruff said he introduced t...
...o have late children but fear loss in fertility ca...and can use it when they want their children.// Th...ertility to store their embryo without fear of loo...ll be very useful for cancer patients who are plan...
Other Medicine News:Health News:Does Magnet Therapy Posses Healing Powers? 2Health News:New Generation Clinical Trials Could Save Time And Money, Improve Patient Care 2
(Date:8/26/2008)...DIANAPOLIS, Aug. 26 /- Semafore Pharm...rnational Congress on Targeted Therapies,in Cancer...novel,multi-targeted kinase inhibitors that demons...al studies., A novel and proprietary molecular sc...ling allowing for the design of pan-PI3 kinase inh...
(Date:8/26/2008)...BURN, Mass., Aug. 26 /- Cambridge Res...release of the Maestro(TM) EX In,Vivo Imaging Syst...-art,FLEX technology and becomes the entry-level i...ng., (Photo: http://www.newscom.com/cgi-bin/prnh...a significant advancement of CRi,s unique,solid-st...
(Date:8/26/2008)...ATTLE, Aug. 26 /- Omeros Corporation ...m a Phase 1/Phase 2 trial investigating,OMS103HP i...construction,surgery. OMS103HP is an investigation...gation solution and is designed to improve postope...ive pain and allow patients an,earlier return to w...
(Date:8/25/2008)...LLESLEY HILLS, Mass., Aug. 25 /- Jose...assets of Spherics, Inc. ("Spherics") for,the bene...eutical,intellectual property will be sold at a se... an extended release formulation of Levodopa-Carbi...or Parkinson,s disease, with global,sales estimate...
Breaking Medicine Technology:Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3CRi Announces New Maestro(TM) EX In Vivo Imaging System with Improved Performance and an Affordable Price 2Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery 2Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels 2Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss 2866 1Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss 2866 2Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss 2866 3NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 7263 1NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 7263 2NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 7263 3NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 7263 4TVM Capital Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 7260 1TVM Capital Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 7260 2TVM Capital Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 7260 3TVM Capital Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 7260 4TVM Capital Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 7260 5Creating unconventional metals 7259 1Creating unconventional metals 7259 2
The EZY Close post op shoe's flap-on-flap closure provides a secure fit and can accommodate even the bulkiest of dressing. Perfect for older patients with limited hand dexterity.
This popular post op shoe provides quality care at an outstanding value. The semi-rigid outsole provides stability and minimizes flexure.
...for patients who experience severe plantar fasciit... fibrous tissue that can occur after rest periods ...ing. The continuous tension and fixed position red...d helps stretch the Achilles tendon to provide rel...
Bird and Cronin, Inc. is a leading manufacturer of Patient Footwear, Orthopedic Softgoods, and Specialty Patient Care Products. Our products are of the highest quality and available in the USA and In
Medicine Products: